HG-14-10-04

• UNSPSC Description:

  HG-14-10-04 is a potent ALK and mutant EGFR inhibitor with IC50s of 20 nM, 15.6 nM, 22.6 nM and 124.5 nM for ALK, EGFRLR/TM, EGFR19del/TM/CS and EGFRLR/TM/CS, respectively. HG-14-10-04 can be used to research anticancer[1][2].

• Target Antigen:

  Anaplastic lymphoma kinase (ALK); EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/HG-14-10-04.html

• Solubility:

  DMSO : 20 mg/mL (ultrasonic)

• Smiles:

  ClC1=CN=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)N=C1C5=CNC6=CC=CC=C65

• Molecular Weight:

  532.08

• References & Citations:

  [1]U.S. Pat. Appl. Publ. (2012), US 20120028924 A1|[2]Chen H, et al. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65(9):6840-6858.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1356962-34-9